Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02036632 · ClinicalTrials.gov registry record · Phase 1
Eye Patch Therapy for Central Serous Retinopathy (CSR)
A Phase 1 study, sponsored by Washington University School of Medicine.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT02036632 is a Phase 1 study that has completed, run by Washington University School of Medicine. The registered enrollment target is 12 participants.
The verdict
NCT02036632, a Phase 1 study, has completed, sponsored by Washington University School of Medicine.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
First, this study will investigate the viability of 24-hour eye patching as a potential treatment modality for CSR. Second, this study will assess a potential physiologic explanation for CSR, namely if inhibition of photic stimulation of the diseased retina will aid in ameliorating disease severity and disease duration.
Interventions
- DEVICE Eye Patching
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2012-11 |
| Est. Completion | 2015-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02036632
The ClinicalTrials.gov registry entry for NCT02036632 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Eye Patching is the first listed.
NCT02036632 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02036632 about?
NCT02036632 is a clinical study titled "Eye Patch Therapy for Central Serous Retinopathy (CSR)". First, this study will investigate the viability of 24-hour eye patching as a potential treatment modality for CSR. Second, this study will assess a potential physiologic explanation for CSR, namely if inhibition of photic stimulation of the diseased retina will aid in ameliorating disease severity ...
What is the current status of trial NCT02036632?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2012-11. Estimated completion is 2015-01.
What interventions are being tested in trial NCT02036632?
The interventions under investigation include: Eye Patching (DEVICE).
Who is sponsoring clinical trial NCT02036632?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.